In this context, DDLPS is considered a sarcoma histotype suitable for immune therapy approaches, as reported in the SARC-028 clinical trial, where 20% of patients with metastatic DDLPS showed tumor responses to pembrolizumb (i.e., anti-PD-L1 antibody) [51]. The gene discussed is CD274; the disease is neoplasm.